Beximco Pharmaceuticals Ltd.
25th October 2011
Beximco Pharma introduces Dinovo
Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced Dinovo®, a combination of Naproxen and Esomeprazole Magnesium, for the first time in Bangladesh. Dinovo® is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis without causing NSAID-associated gastric injury.
Though NSAIDs are effective against pain and inflammation, these can cause gastric injury and ulcer on long term use. Hence, PPIs are usually routinely prescribed with NSAIDs to protect against potential gastric injury. However, many patients may not get full benefit of protective PPI therapy as they forget to take the PPI or feel uncomfortable to maintain the timing of PPI intake.
Combination of naproxen and esomeprazole is an effective and well tolerated treatment option for osteoarthritis patients at risk of developing NSAID-associated gastric ulcers. A single tablet delivers both the proven pain relief of naproxen with the gastric ulcer risk reduction of esomeprazole in every dose of the medication.
Dinovo® is specially designed for ulcer risk reduction. Immediate-release esomeprazole is released first in the stomach and reduces gastric acid secretion by inhibiting the enzyme H+K+-ATPase – the acid pump and inhibits both basal and stimulated acid secretion. The release of esomeprazole is followed by the dissolution of naproxen in the small intestine. The enteric coating prevents the release of naproxen at pH <5, providing protection against possible local gastric toxicity of naproxen. After reaching intestine, naproxen is released and gets absorbed in blood to exert anti-inflammatory and analgesic action.